Navigation Links
Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia
Date:11/20/2008

    PRELIMINARY TOP LINE RESULTS OF FIRST PHASE III TRIAL SHOW SIGNIFICANT
     DECREASES IN PAIN AND FATIGUE, AND IMPROVEMENT IN DAILY FUNCTION, IN
                            FIBROMYALGIA PATIENTS

PALO ALTO, Calif., and BRUSSELS, Belgium, Nov. 20 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) and UCB (Euronext Brussels: UCB) announced today positive preliminary top-line results from the first of two Phase III pivotal clinical trials of sodium oxybate (JZP-6) for the treatment of fibromyalgia. The randomized, double-blind, placebo-controlled study achieved its primary endpoints, demonstrating that sodium oxybate significantly decreased pain and fatigue, and improved daily function, in patients with fibromyalgia.

"There is a significant unmet need in diagnosing and treating millions of patients with fibromyalgia. Potential new treatments that address the various symptoms can have a significant impact on patients' quality of life," said I. Jon Russell, M.D., Ph.D., the study's lead investigator and Associate Professor of Medicine, Division of Clinical Immunology and Rheumatology, and Director, University Clinical Research Center, University of Texas Health Science Center at San Antonio.

The 14-week study included 548 adult patients with fibromyalgia randomized to one of three treatment arms: sodium oxybate 4.5 g/night, sodium oxybate 6 g/night or placebo. The primary outcome measure, viewed by both U.S. and EU regulatory authorities as a clinically meaningful endpoint, was the proportion of patients who achieved at least 30 percent reduction in pain from baseline to endpoint based on the Pain Visual Analog Scale (VAS). In the EU it is also considered that Fibromyalgia Impact Questionnaire (FIQ) data is equally relevant. FIQ data are considered supportive data by U.S. regula
'/>"/>

SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia
2. Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351
3. Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program
4. Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire dAngers for Phase II Clinical Trial in Huntingtons Disease
5. VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease
6. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
7. Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
8. VIA Pharmaceuticals Announces Conference Call and Webcast to Discuss VIA-2291 Phase 2 Data Presentations at AHA
9. Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium
10. Raptor Pharmaceuticals Provides Update on Targeting Platforms
11. Oramed Pharmaceuticals Chosen to Present Results of GLP-1 Analog Enteral Administration Study at the Diabetes Technology Societys Eighth Annual Meeting (November 13-15, 2008; Bethesda, Maryland)

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)....C., Nov. 25 Cempra Pharmaceutical... president and chief executive officer, will prese...nference at 8:50 a.m. EST, December 1, 2009, at Th...nandes will provide an overview of the company,s t...eatment of drug-resistant pathogens including MRSA...
(Date:11/25/2009)...Netherlands and JOHANNESBURG, November 25 /PRNewsw...and Pyxis Discovery announced today,that they have...t both,companies, services. , Pyxis,s wor...y expertise,will be coupled with iThemba,s service...stry support to projects identified through Pyxis,...
(Date:11/24/2009)... Md., Nov. 24 /PRNewswire-Asia/ -- Chindex Interna...ng independent American provider of Western,health...c of China, today,announced that the Company will ...ealth Care Conference, to be held December 1 - 2, ...agement is currently scheduled to present at 11:30...
Breaking Medicine Technology:iThemba Pharmaceuticals (Pty) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer a Combined Service Offering 2Chindex International to Present at Piper Jaffray Health Care Conference 2Pharmavite Pilots LearnSomething Interactive Digital Signage to Reach Shoppers in Stores 55983 1Pharmavite Pilots LearnSomething Interactive Digital Signage to Reach Shoppers in Stores 55983 2Pharmavite Pilots LearnSomething Interactive Digital Signage to Reach Shoppers in Stores 55983 3VisEn Launches New Annexin Vivo 750 Fluorescence Molecular Imaging Agent 13792 1VisEn Launches New Annexin Vivo 750 Fluorescence Molecular Imaging Agent 13792 2VisEn Launches New Annexin Vivo 750 Fluorescence Molecular Imaging Agent 13792 3Interim Phase II Data Presented at XIV World Congress of Neurological Surgery Supports Potential of Peregrines Cotara 28R 29 for Treatment of Brain Ca 4935 1Interim Phase II Data Presented at XIV World Congress of Neurological Surgery Supports Potential of Peregrines Cotara 28R 29 for Treatment of Brain Ca 4935 2Interim Phase II Data Presented at XIV World Congress of Neurological Surgery Supports Potential of Peregrines Cotara 28R 29 for Treatment of Brain Ca 4935 3Interim Phase II Data Presented at XIV World Congress of Neurological Surgery Supports Potential of Peregrines Cotara 28R 29 for Treatment of Brain Ca 4935 4Interim Phase II Data Presented at XIV World Congress of Neurological Surgery Supports Potential of Peregrines Cotara 28R 29 for Treatment of Brain Ca 4935 5
...ts with multiple sclerosis, remained relapse-fre...- New data demonstrate 89% of patients free from a...S - three years after starting treatment, - MS, a...y, affects 2.5 million people worldwide i...lings planned before end of 2009 in US and EU, EA...
...sis of methotrexate,resistance and differences in ...The first analysis,of the genetic determinants of ... childhood acute lymphoblastic leukemia (ALL) coul...d treatments to overcome it,according to a St. Jud...s use in ALL, methotrexate is widely used to treat...
Other Medicine Technology:FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 2FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 3FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 4FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 5FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 6St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia 2St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia 3St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia 4
(Date:11/27/2009)..., , KIBBUTZ SHAMIR, Israel, Nov. 27 /PRNewsw...sdaq: SHMR ) ( "Shamir" ), a leading provider of ...ic lens market, announced today that its board of ...an aggregate amount of US$ 10 million (approximate...9 representative rate of exchange), or approximate...
(Date:11/27/2009)... Voyant Health™ anno...chigan) has licensed its TraumaCad Enterprise orth...d workflow solution. , (P...nounced today that Spectrum Health (Grand Rapids, ...thopedic templating solution and its TraumaCad Ext...
(Date:11/26/2009)..., , PRINCETON, N.J., Nov. 27 /PRNewswire/...ill almost double over the next 25 years and annua...hit $336 billion, up from $113 billion today, acco...f Diabetes Care . The National Changing Diabete..., commissioned the analysis by a team from the Uni...
(Date:11/26/2009)... No more letters from the ...,personalized text messages from Santa , ...fort to increase operational efficiencies at the N... to help keep children all over the globe informed...Elves in Santa’s research department have id...
(Date:11/25/2009)..., , EDINA, Minn., Nov. 25 /PRNewswire-USNew...hey think of their dentist. But a chiropractor ca...s for the Temporal-Mandibular Joint, which is wher...skull (temporal bone). ,, The most common symp... chewing, clicking or popping of the jaw. But man...
Breaking Medicine News(10 mins):Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 2Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 3Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 2Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 3Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 4Health News:Text Messages from Santa | Santa goes GREEN by going MOBILE for The March of Dimes 2
...ACH, Calif., June 25 Function Drinks,announced to...NIGHT LIFE, a,physician,s take on supporting sexua...xtract macuna pruriens and the amino acid, tyrosin...d,cnidium help support healthy circulation. Functi...
...ati, OH, June 25, 2008--Bassinet use in 2006 was n...more than 45% of infants between the ages of 0-2 m...ety. In fact, the Consumer Product Safety Commiss...of Pediatrics (AAP) revised its recommendations fo...
...DOVA, Calif., June 24 Executive,Director, Diana F...s who,need financial assistance to help them pay f...ademic year State Nursing Assumption Program of Lo...ces to help them pay for their postsecondary educa...
...on could mean fewer shots for 4 to 6 year-olds in ...e (NYSE:,GSK) announced today that the U.S. Food a...M) [Diphtheria and Tetanus Toxoids and Acellular P...lio,diseases in one shot., "Children 4 to 6 years...
...Y, Mo., June 24 DST Systems, Inc.,(NYSE: DST ) w...uarter,ending June 30, 2008, on Tuesday, July 22, ...tock Exchange., The Company will host a conferenc...arnings Release. For international,callers, the di...
...a., June 24 Alan J. Zuccari,President & CEO of Ha...,Action Committee (PAC) member for the American He...k with the committee., "It,s an honor to be recog...are.", Below is the article which will be feature...
Other Medicine News:Health News:Function Drinks Launches New Product to Support Sexual Health 2Health News:Bedsharing and bassinets: 2 new studies assess the risks 2Health News:Nursing Loan Forgiveness Programs -- More Applicants Needed by June 30, 2008 2Health News:FDA Approves KINRIX(TM) - New Combination Vaccine for Children 2Health News:FDA Approves KINRIX(TM) - New Combination Vaccine for Children 3Health News:DST Systems, Inc. Announces Notification of Earnings Release Date 2Health News:Alan J. Zuccari Featured by the American Health Care Association as a June PAC Member 2
ExcaliburPlus PC, 220V, 50Hz
Elmed BC 50 Standard
Hudson Burr
Cushing Burr
Medicine Products: